“Things are changing, and in many cases, it’s just not viable to bring in small quantities of pharmaceuticals anymore from the UK” Pierre Fava, Chemimart Group CEO told the Malta Business Weekly when contacted with about the impact of Brexit on pharmaceutical products.

Increase in costs, changes in legislation, licencing, and even language barriers on the packaging were among Fava’s concerns.

Read the full story on The Malta Business Weekly.